Defunct Company
Total Trials
23
As Lead Sponsor
19
As Collaborator
4
Total Enrollment
2,916
NCT00339131
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 30, 2006
Completion: Jan 31, 2007
NCT00458952
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Phase: Phase 1/2
Start: Apr 30, 2007
Completion: Jun 30, 2011
NCT00514501
Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome
Phase: Phase 2
Start: May 31, 2007
Completion: Dec 31, 2008
NCT00712829
Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents
Start: May 31, 2008
Completion: Jan 31, 2009
NCT00659984
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Start: Jun 30, 2008
Completion: Nov 30, 2010
NCT00696930
Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
Completion: Not specified
NCT00911729
Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
Phase: N/A
Start: Apr 30, 2009
NCT00874614
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Start: Jun 4, 2009
Completion: Feb 28, 2021
NCT01048086
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
Role: Collaborator
Start: Jun 30, 2009
Completion: Nov 30, 2013
NCT00992745
A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer
Start: Oct 31, 2009
Completion: Sep 30, 2011
NCT01730417
Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG
Start: Nov 30, 2009
Completion: Jul 31, 2011
NCT00747825
Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma
Start: Dec 31, 2009
NCT00992173
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
Start: Jan 31, 2010
NCT01261754
A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers
Start: Dec 31, 2010
NCT01279785
A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy
Start: Mar 31, 2011
NCT01572701
Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection
Start: Jan 31, 2012
NCT01615406
A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer
Start: Apr 30, 2012
NCT01654874
99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404
Start: Jul 31, 2012
NCT01667536
A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology
Start: Aug 31, 2012
Completion: Dec 31, 2013
NCT01583842
124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study
Phase: Early Phase 1
Start: Apr 9, 2013
Completion: Feb 25, 2021
NCT02615067
Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer
Phase: Phase 3
Start: Dec 31, 2015
Completion: Dec 28, 2017
NCT04447937
Immunodeficiency in MS
Start: Jun 29, 2020
Completion: Jul 30, 2021